View the article online at http://citywire.co.uk/wealth-manager/article/a749372
Barclays and Aberdeen drag down FTSE
by Daniel Grote on May 06, 2014 at 10:43
The FTSE 100 shed 12 points, or 0.2%, to 6,810, after hitting 6,838 on Friday, the highest level since late February. Barclays and Aberdeen were the biggest fallers, dropping 4.2% and 5.4% to 247.6p and 422p respectively.
Barclays has reported profit before tax of £1.7 billion for the first three months of the year, down from the £1.8 billion the market had been expecting. This represents a 5% year-on-year fall in profits, which Barclays had flagged at its annual general meeting (AGM), stating they would be down ‘slightly’.
Investec analyst Ian Gordon said the figures had not come as a surprise. Adjusted profit before tax is £1.7 billion, in line with us, but £100 million below consensus, which evidently ignored the AGM statement!’ he said.
He said the share price falls were to be expected given disappointing revenues from Barclays Capital, the bank’s investment division. Revenues in that division were down 28%, offsetting stronger performance from its UK retail, corporate and Barclaycard divisions.
Aberdeen meanwhile reported profits of £217 million for the six months to the end of March, down 3% on the same period last year, driven largely by decreasing margins on the funds it manages.
Aberdeen recently finalised the acquisition of Scottish Widows Investment Partnership (Swip) from Lloyds Banking Group (LLOY.L), but despite the increased earnings this will bring, Numis analyst David McCann still rates the stock as a ‘hold’.
‘The stock is not as cheap as it was in the past and the earnings growth outlook is now lower than it was (even with the additional expected Swip earnings accretion),’ he said.
AstraZeneca (AZN.L) continued to slide as the pharmaceutical group prepares to step up its defence against US rival Pfizer’s takeover bid for the company. It fell 94p, or 2%, to £47.13.
Star fund manager Neil Woodford has weighed into the debate over the takeover bid as he prepares to launch his new CF Woodford Equity Income fund, describing Pfizer’s initial bid for the group as ‘opportunistic’ and saying he believed Astra had ‘an exciting future as an independent entity’.
News sponsored by:
As the UK coalition government strives to rebalance the national economy, so called 'reshoring' looks set to play an increasingly important role in economic recovery.
Today's top headlines
With talk on interest rates on the horizon, our latest roundtable debate covers income investing against a changing backdrop
More about this:
Look up the funds
Look up the shares
- Barclays PLC (BARC.L)
- AstraZeneca PLC (AZN.L)
- Pearson PLC (PSON.L)
- Melrose Industries PLC (MRON.L)
- St. James's Place PLC (SJP.L)